GERPINNES PHARMA
0475.932.676 · rovalta.com · 24/09/2026
ACTIVE
GERPINNES PHARMA
Financial year 2025 · closed on 31/12/2025
Net result
12,4 k €
+128.7% YoY
Gross margin
408,4 k €
+48.7% YoY
Equity
438,9 k €
+2.9% YoY
Overview
What does GERPINNES PHARMA do?
GERPINNES PHARMA is a Public limited company incorporated in 2001. Its main activity is: Dispensing chemist in specialised stores. Its registered office is in Gerpinnes.
Legal situation
● Normal situation
BCE/KBO no. / VAT
BE 0475.932.676
Incorporation
24/10/2001
Legal form
Public limited company
Registered office
Place de la Halle(GER) 3
6280 Gerpinnes · WallonieSee on map
6280 Gerpinnes · WallonieSee on map
Contributed capital
862 000,00 €
Latest accounts
31/12/2025
Activities (NACE)
Joint committees (1)
- 313
Signals
ProfitablePositive cashflowPositive EBITDAHealthy social debts
Available with a Rovalta subscriptionTry for 7 days
Financials
Trend over 20 financial years
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | ||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||||||||||||||||||||||||||||||||
| Gross margin | 408,4 k € | +48.7% | 274,6 k € | -16.1% | 327,4 k € | +4.5% | 313,3 k € | -4.5% | 328 k € | +8.6% | 302 k € | +0.2% | 301,5 k € | +121% | 136,3 k € | -54.7% | 301,2 k € | +50.6% | 200,1 k € | +3755% | 5,2 k € | +78.9% | 2,9 k € | +411% | -933,9 € | -103% | 31,7 k € | +48.4% | 21,3 k € | +38.4% | 15,4 k € | -28.1% | 21,4 k € | +3.2% | 20,8 k € | +12.9% | 18,4 k € | +7.1% | 17,2 k € |
| EBITDA | 172,8 k € | +62.4% | 106,4 k € | -18.3% | 130,3 k € | +33.2% | 97,8 k € | +41.9% | 68,9 k € | +17.6% | 58,6 k € | +207% | 19,1 k € | +111% | -179,3 k € | -432% | -33,7 k € | -279% | 18,8 k € | +352% | 4,2 k € | +121% | 1,9 k € | +197% | -1,9 k € | -106% | 30,7 k € | +50.4% | 20,4 k € | +40.8% | 14,5 k € | -29.4% | 20,5 k € | +3.2% | 19,9 k € | +13.5% | 17,5 k € | +7.5% | 16,3 k € |
| Operating result | -21,3 k € | +75.4% | -86,6 k € | -6.5% | -81,4 k € | +17.3% | -98,4 k € | -150% | -39,4 k € | -6.4% | -37 k € | +51.4% | -76,1 k € | +68.7% | -243,4 k € | -142% | -100,7 k € | -402% | -20,1 k € | -916% | -2 k € | +53.5% | -4,2 k € | +46.6% | -8 k € | -130% | 26,2 k € | +64.5% | 15,9 k € | +27.5% | 12,5 k € | -19.6% | 15,6 k € | +4.2% | 14,9 k € | +18.8% | 12,6 k € | +10.8% | 11,3 k € |
| Net result | 12,4 k € | +129% | -43,1 k € | -8.3% | -39,8 k € | +11.0% | -44,7 k € | -1099% | -3,7 k € | +62.7% | -10 k € | +82.6% | -57,4 k € | +79.3% | -277,4 k € | -1547% | -16,8 k € | +10.1% | -18,7 k € | -574% | 4 k € | +112% | 1,9 k € | +1377% | 126,3 € | -99.4% | 22,2 k € | +66.7% | 13,3 k € | +22.9% | 10,8 k € | +26.4% | 8,6 k € | -2.5% | 8,8 k € | -3.8% | 9,1 k € | +43.2% | 6,4 k € |
| Balance sheet | |||||||||||||||||||||||||||||||||||||||
| Equity | 438,9 k € | +2.9% | 426,6 k € | -9.2% | 469,7 k € | -7.8% | 509,5 k € | -8.1% | 554,1 k € | +329% | -242,1 k € | -4.3% | -232,1 k € | -32.8% | -174,8 k € | -270% | 102,6 k € | -14.1% | 119,5 k € | -13.6% | 138,2 k € | +2.9% | 134,2 k € | +1.4% | 132,4 k € | +0.1% | 132,2 k € | +20.1% | 110,1 k € | +13.7% | 96,8 k € | +12.6% | 86 k € | +11.1% | 77,4 k € | +12.8% | 68,6 k € | +15.4% | 59,5 k € |
| Total assets | 2,1 M € | -3.1% | 2,1 M € | -8.9% | 2,4 M € | -7.3% | 2,5 M € | +49.3% | 1,7 M € | +53.5% | 1,1 M € | -15.3% | 1,3 M € | +41.9% | 923,3 k € | -26.3% | 1,3 M € | -10.2% | 1,4 M € | +4.4% | 1,3 M € | +0.8% | 1,3 M € | -1.1% | 1,3 M € | -1.9% | 1,4 M € | +1.0% | 1,4 M € | +0.1% | 1,3 M € | +8.8% | 1,2 M € | -3.7% | 1,3 M € | -1.3% | 1,3 M € | -0.5% | 1,3 M € |
| Cash | 302,1 k € | +0.8% | 299,8 k € | +2.4% | 292,9 k € | -34.0% | 443,7 k € | -10.1% | 493,4 k € | +137% | 208 k € | -44.3% | 373,3 k € | +93.3% | 193,1 k € | +460% | 34,5 k € | +0.5% | 34,4 k € | +9512% | 357,4 € | -14.0% | 415,5 € | -22.4% | 535,1 € | -18.9% | 660,1 € | +109% | 316,1 € | -73.2% | 1,2 k € | +487% | 200,7 € | -26.1% | 271,7 € | +71.7% | 158,3 € | +5.5% | 150 € |
| Debts | 1,6 M € | -4.5% | 1,7 M € | -8.8% | 1,9 M € | -7.1% | 2 M € | +77.0% | 1,1 M € | -15.1% | 1,4 M € | -12.4% | 1,5 M € | +41.1% | 1,1 M € | -5.0% | 1,1 M € | -9.7% | 1,3 M € | +6.3% | 1,2 M € | +0.6% | 1,2 M € | +3998% | 29 k € | -47.6% | 55,4 k € | -95.5% | 1,2 M € | -0.9% | 1,3 M € | +8.5% | 1,2 M € | -4.6% | 1,2 M € | -2.0% | 1,2 M € | -1.3% | 1,3 M € |
| Other | |||||||||||||||||||||||||||||||||||||||
| Workforce | – | – | – | – | – | 5,0 ETP | 0.0% | 5,0 ETP | -19.4% | 6,2 ETP | -13.9% | 7,2 ETP | +16.1% | 6,2 ETP | – | – | – | – | – | – | – | – | – | – | |||||||||||||||
Estimate
Indicative valuation
As an indication, this company is worth
between 500 k€ and 1 M€
See the valuationGovernance
Board of directors
Seen on filing of 31/12/2025 · 2 active · 13 ended
Active mandates
FINPHARMA SA
ActiveActive
Ended mandates
Financials
Annual accounts
Full financial information
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|
| Type of account | Micro model | Micro model | Micro model | Micro model | Micro model | Abridged model |
| Start of the financial year | 01/01/2025 | 01/01/2024 | 01/01/2023 | 01/01/2022 | 01/01/2021 | 01/01/2020 |
| Closing of the financial year | 31/12/2025 | 31/12/2024 | 31/12/2023 | 31/12/2022 | 31/12/2021 | 31/12/2020 |
| Length of the financial year | 12 months | 12 months | 12 months | 12 months | 12 months | 12 months |
| Filing date | 30/06/2026 | 14/07/2025 | 06/08/2024 | 23/08/2023 | 18/08/2022 | 09/08/2021 |
| General meeting | 16/05/2026 | 17/05/2025 | 18/05/2024 | 20/05/2023 | 21/05/2022 | 15/05/2021 |
| Currency of the financial year | EUR | EUR | EUR | EUR | EUR | EUR |
| NBB quality label | Satisfying controls | Satisfying controls | Satisfying controls | Satisfying controls | Satisfying controls | Satisfying controls |
Ratios
Financial ratios
Looking for more information about this company?
Try for 7 daysFilings
Annual accounts filings
20 filings with the NBB
| Model | Closing | General meeting | Filed | Language | Document |
|---|---|---|---|---|---|
| Micro model | 31/12/2025 | 16/05/2026 | 30/06/2026 | French | |
| Micro model | 31/12/2024 | 17/05/2025 | 14/07/2025 | French | |
| Micro model | 31/12/2023 | 18/05/2024 | 06/08/2024 | French | |
| Micro model | 31/12/2022 | 20/05/2023 | 23/08/2023 | French | |
| Micro model | 31/12/2021 | 21/05/2022 | 18/08/2022 | French | |
| Abridged model | 31/12/2020 | 15/05/2021 | 09/08/2021 | French | |
| Abridged model | 31/12/2019 | 16/05/2020 | 25/08/2020 | French | |
| Abridged model | 31/12/2018 | 04/05/2019 | 16/05/2019 | French | |
| Abridged model | 31/12/2017 | 05/05/2018 | 10/05/2018 | French | |
| Abridged model | 31/12/2016 | 06/05/2017 | 11/05/2017 | French | |
| Abridged model | 31/12/2015 | 07/05/2016 | 10/05/2016 | French | |
| Abridged model | 31/12/2014 | 02/05/2015 | 12/05/2015 | French | |
| Abridged model | 31/12/2013 | 03/05/2014 | 09/05/2014 | French | |
| Abridged model | 31/12/2012 | 04/05/2013 | 08/05/2013 | French | |
| Abridged model | 31/12/2011 | 05/05/2012 | 23/05/2012 | French | |
| Abridged model | 31/12/2010 | 07/05/2011 | 16/05/2011 | French | |
| Abridged model | 31/12/2009 | 08/05/2010 | 30/05/2010 | French | |
| Abridged model | 31/12/2008 | 09/05/2009 | 15/05/2009 | French | |
| Abridged model | 31/12/2007 | 10/05/2008 | 13/05/2008 | French | |
| Abridged model | 31/12/2006 | 12/05/2007 | 02/07/2007 | French |
Valuation
Estimate
Indicative valuation
Order of magnitude
As an indication, this company is worth
between 500 k€ and 1 M€
The detail comes with the Business plan: low and high bounds, the valuation bridge for each financial year, transaction multiples by sector and size, group valuation and exports.
Disclaimer
Indicative estimate based on public sector multiples and the filed annual accounts. It is neither a certified valuation nor financial or investment advice.
Directors & structure
Governance
Board of directors
Seen on filing of 31/12/2025 · 2 active · 13 ended
Active mandates
FINPHARMA SA
ActiveActive
Ended mandates
Shareholders
Ownership and network
Looking for more information about this company?
Try for 7 daysPublications
Belgian Official Gazette
Belgian Official Gazette publications
- Mandates19/12/2024DEMISSIONS, NOMINATIONS
- Mandates18/01/2022DENOMINATION - CAPITAL, ACTIONS - STATUTS (TRADUCTION, COORDINATION, AUTRES MODIFICATIONS, )
- Other23/09/2019STATUTS (TRADUCTION, COORDINATION, AUTRES MODIFICATIONS, )
- Mandates21/01/2019DEMISSIONS, NOMINATIONS
- Mandates08/08/2018DEMISSIONS, NOMINATIONS
- Restructuring06/03/2017OBJET - RUBRIQUE RESTRUCTURATION (FUSION, SCISSION, TRANSFERT PATRIMOINE, ETC...)
- Restructuring23/08/2016RUBRIQUE RESTRUCTURATION (FUSION, SCISSION, TRANSFERT PATRIMOINE, ETC...)
- Mandates21/05/2013DEMISSIONS, NOMINATIONS
Source: Belgian Official Gazette
Similar companies
Competition
Similar companies
A company's peers, by sector and size, are included in the Business plan.
See the Business planTimeline
Timeline
- 2025Annual accounts 202512,4 k €↑
- 2024Annual accounts 2024-43,1 k €↓
- 2023Annual accounts 2023-39,8 k €↑
- 2022Annual accounts 2022-44,7 k €↓
- 2021Annual accounts 2021-3,7 k €↑
- 2021Name changeGERPINNES PHARMA
- 2020Annual accounts 2020-10 k €↑
- 2019Annual accounts 2019-57,4 k €↑
- 2018Annual accounts 2018-277,4 k €↓
- 2017Annual accounts 2017-16,8 k €↑
- 2016Annual accounts 2016-18,7 k €↓
- 2015Annual accounts 20154 k €↑
- 2014Annual accounts 20141,9 k €↑
- 2013Annual accounts 2013126,3 €↓
- 2012Annual accounts 201222,2 k €↑
- 2011Annual accounts 201113,3 k €↑
- 2010Annual accounts 201010,8 k €↑
- 2009Annual accounts 20098,6 k €↓
- 2008Annual accounts 20088,8 k €↓
- 2007Annual accounts 20079,1 k €↑
- 2006Annual accounts 20066,4 k €
- 2006Name changePHARJAB
- 24/10/2001IncorporationPublic limited company